{"entity":{"id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","aka":[],"tldr":"Vaccines tailored to each patient's tumour mutations are showing real benefit but cost a fortune to make. Automate the whole process so a personalised vaccine costs about as much as a course of chemotherapy.","summary":"Individualised neoantigen mRNA vaccines have shown reduced recurrence in melanoma with pembrolizumab (phase 2b, with phase 3 ongoing) and immune responses in pancreatic cancer, but require bespoke sequencing, epitope selection and GMP manufacture per patient at very high cost. The proposal is an engineering programme for end-to-end automation: standardised sample-to-sequence pipelines, validated epitope prediction, continuous-flow mRNA synthesis and formulation in closed robotic units sited regionally, and regulatory acceptance of platform-based release testing, targeting a manufactured cost under a few thousand dollars and turnaround under three weeks.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)","url":"https://doi.org/10.1038/nrclinonc.2017.31"}],"tags":[],"related":[],"cancers":["melanoma","pancreatic"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["intismeran-autogene","autogene-cevumeran"],"companies":["moderna","biontech"],"institutions":[],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-immunotherapy-response","b-dormancy-mrd"],"keyPapers":["paper-prasad-nat-rev-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Automated regional manufacturing reduces per-patient vaccine cost by over 90% and turnaround to under three weeks without loss of immunogenicity, making adjuvant personalised vaccination affordable for common cancers if phase 3 trials confirm efficacy.","rationale":"The science of neoantigen vaccination is maturing; if it works, access will be decided by manufacturing cost. The COVID-19 mRNA scale-up showed the platform can be industrialised.","test":"Build one automated regional unit and demonstrate cost, turnaround and product equivalence against conventional manufacture in an ongoing adjuvant vaccine trial.","maturity":"early-clinical","actor":"industry","cost":"large","horizonYears":6},"route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"}],"term":[{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/"}]}}